A Study of Mosliciguat in PH-ILD

Inclusion Criteria:

• Participants willing and able to provide informed consent

• Participants with diagnosis of Interstitial Lung Disease (ILD). Diagnosis will beconfirmed by a high-resolution computerized tomography (HR-CT) scan showing diffuseparenchymal disease. Eligible diagnosed diseases include:

1. Idiopathic interstitial pneumonia (IIP)

2. Chronic hypersensitivity pneumonitis

3. ILD associated with connective tissue disease (CTD) with a forced vitalcapacity (FVC) < 70% of predicted

• Confirmed pulmonary hypertension (PH) by right heart catheterization (RHC).

• Ability to perform 6MWD ≥100 meters.

Exclusion Criteria:

• Diagnosis of PH Group 1 (eg. pulmonary arterial hypertension), Group 2 (related toleft-heart dysfunction), Group 4 (eg, chronic thromboembolic pulmonaryhypertension), or Group 5 (eg, unclassified).

• Exacerbation of underlying lung disease within 28 days prior to randomization.

• Initiation of pulmonary rehabilitation within 28 days prior to randomization.

• Receiving >10 L/min of oxygen supplementation by any mode of delivery at rest atBaseline.

• History or intolerance to or lack of efficacy with mosliciguat or sGC stimulators oractivators.

• Receipt of investigational, or experimental therapy within 42 days OR 5 half-livesprior to randomization.

Note: Other inclusion and exclusion criteria may apply.